De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Spyre Therapeutics Beheer

Beheer criteriumcontroles 0/4

De CEO Spyre Therapeutics' is Cameron Turtle, benoemd in Oct2023, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.17M, bestaande uit 1.7% salaris en 98.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.47% van de aandelen van het bedrijf, ter waarde $ 21.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1 jaar en 1.3 jaar.

Belangrijke informatie

Cameron Turtle

Algemeen directeur

US$16.2m

Totale compensatie

Percentage CEO-salaris	1.7%
Dienstverband CEO	less than a year
Eigendom CEO	1.5%
Management gemiddelde ambtstermijn	1yrs
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08

Aeglea BioTherapeutics EPS misses by $0.14

May 10

Aeglea completes patient randomization in late-stage pegzilarginase trial

May 03

What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition

Mar 17

Analyse CEO-vergoeding

Hoe is Cameron Turtle's beloning veranderd ten opzichte van Spyre Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$186m
Mar 31 2024	n/a	n/a	-US$364m
Dec 31 2023	US$16m	US$273k	-US$339m

Compensatie versus markt: De totale vergoeding ($USD 16.17M ) Cameron } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Cameron te vergelijken met de prestaties van het bedrijf.

CEO

Cameron Turtle (34 yo)

less than a year

Tenure

US$16,174,660

Compensatie

Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Cameron Turtle	CEO & Director	less than a year	US$16.17m	1.47% $ 20.5m
Scott Burrows	Chief Financial Officer	1.1yrs	US$7.55m	0.030% $ 417.7k
Heidy King-Jones	Chief Legal Officer & Corporate Secretary	1.1yrs	US$6.93m	0% $ 0
Janet Gunzner-Toste	Senior Vice President of Operations	no data	geen gegevens	geen gegevens
Brian Connolly	Chief Technical Officer	less than a year	geen gegevens	geen gegevens
Eric McIntyre	Vice President of Finance & Investor Relations	no data	geen gegevens	geen gegevens
James Myers	Vice President of Quality & Compliance	no data	geen gegevens	geen gegevens
Kelly Boothe	Senior Director of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Justin LaFountaine	Senior Vice President of Corporate Development	no data	geen gegevens	geen gegevens
Melissa Cooper	Senior Vice President of People	no data	geen gegevens	geen gegevens
James Kastenmayer	Consultant	1.4yrs	US$865.79k	geen gegevens
Joshua Friedman	Senior Vice President of Clinical Development	less than a year	geen gegevens	geen gegevens

1.0yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SYRE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Cameron Turtle	CEO & Director	less than a year	US$16.17m	1.47% $ 20.5m
Daniel Von Hoff	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Matthew Vander Heiden	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Keith Flaherty	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Jeffrey Albers	Independent Chairman of the Board	less than a year	US$433.57k	0.067% $ 943.5k
Arthur Frankel	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Wayne Klohs	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Tomas Kiselak	Independent Director	1.3yrs	US$658.43k	0.80% $ 11.1m
Mark McKenna	Independent Director	less than a year	geen gegevens	0% $ 0
Laurie Stelzer	Independent Director	less than a year	US$434.38k	0% $ 0
Michael Henderson	Independent Director	1.3yrs	US$660.78k	0% $ 0
Peter Harwin	Independent Director	1.3yrs	US$661.28k	0.80% $ 11.1m

1.3yrs

Gemiddelde duur

44yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SYRE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.

Spyre Therapeutics Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Recent updates

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) acquired Spyre Therapeutics, Inc. for $1.42 million.

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Aeglea BioTherapeutics Announces Resignation of Sandesh Mahatme as Director

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2000 Dynamic Index

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Biotherapeutics, Inc. Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Consensus revenue estimates increase by 36%

Price target decreased to US$9.86

Price target decreased to US$11.00

Aeglea BioTherapeutics, Inc. Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Consensus revenue estimates increase by 76%

President recently bought US$281k worth of stock

Consensus forecasts updated

Price target decreased to US$11.00

Aeglea Biotherapeutics, Inc. Announces Resignation of Sara Brownstein as Class I Director of the Board

Independent Director recently bought US$550k worth of stock

Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

Price target decreased to US$12.43

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Chief Financial Officer recently bought US$263k worth of stock

Consensus revenue estimates increase to US$17.9m

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aeglea BioTherapeutics, Inc. Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for Treatment of Arginase 1 Deficiency in Journal of Inherited Metabolic Disease

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2500 Growth Index

Aeglea Biotherapeutics Doses First Patient in A Phase 1/2 Clinical Trial of Agle-177, A Potential First-In-Class Treatment for Homocystinuria